Investors
Company Profile
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
Financial Reports
Press Releases
ObsEva SA appoints Ben T.G. Tan as VP Commercial & Business Development
press release
September 10, 2014
Geneva, Switzerland, 10 September 2014 – ObsEva, a Swiss-based, specialty biopharmaceutical company dedicated to the development and commercialisation of innovative…
Read moreObsEva SA announced today it was granted JEDI status and European SME status
press release
July 23, 2014
Geneva, Switzerland, 23 July 2014 – ObsEva, a Swiss-based, specialty biopharmaceutical company dedicated to the development of innovative drugs for…
Read moreObsEva SA Announces Appointments to its Board of Directors and Scientific Advisory Board
press release
January 17, 2014
Geneva, Switzerland, 17 January 2014 – ObsEva, a Swiss-based, speciality biopharmaceutical company dedicated to the development of innovative drugs for…
Read moreGeneral Meetings
ObsEva Annual General Meeting 2022
May 18, 2022
ObsEva Annual General Meeting 2021
May 28, 2021
Upcoming Events
Stock Information
Latest Press Release
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
-Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back…
Read moreInvestor Contact
Media Contact
Contacts
ObsEva Switzerland Office
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840
Sign up for news
